目的:探讨平喘固本胶囊联合布地格福对中重度慢性阻塞性肺疾病稳定期的效益。方法:选取2021年11月~2023年11月在广元市中医院呼吸与危重症医学科门诊的慢阻肺稳定期(C、D组) (肺肾两虚证)患者75例,随机分为对照组(单用布地格福)和试验组...目的:探讨平喘固本胶囊联合布地格福对中重度慢性阻塞性肺疾病稳定期的效益。方法:选取2021年11月~2023年11月在广元市中医院呼吸与危重症医学科门诊的慢阻肺稳定期(C、D组) (肺肾两虚证)患者75例,随机分为对照组(单用布地格福)和试验组(平喘固本胶囊联合布地格福),治疗疗程9个月,观察中医证候、CAT评分、肺功能、血气分析及6分钟步行试验在治疗前后的改善情况,同时监测不良反应,评估药物安全性。结果:试验组总有效率为96.8% (35/37),高于对照组(84.3% (31/37), P 2)均较前降低,氧分压(PaO2)、第1秒用力呼气体积(FEV1)、FEV1/用力肺活量(FVC)水平升高。结论:平喘固本胶囊联合布地格福对中重度慢性阻塞性肺疾病稳定期患者具有较好的临床疗效,具有良好的安全性。Objective: To explore the efficacy of Pingchuan Guben Capsules combined with Budgefu in the stable phase of moderate to severe chronic obstructive pulmonary disease. Method: 75 patients with stable chronic obstructive pulmonary disease (COPD) (Group C and D) (lung kidney deficiency syndrome) who were treated in the Respiratory and Critical Care Medicine Clinic of Guangyuan Traditional Chinese Medicine Hospital from November 2021 to November 2023 were randomly divided into a control group (treated with Budgefu alone) and an experimental group (treated with Pingchuan Guben Capsules combined with Budgefu). The treatment course was 9 months. The improvement of TCM syndrome, CAT score, lung function, blood gas analysis, and 6-minute walk test before and after treatment were observed, and adverse reactions were monitored to evaluate drug safety. Result: The total effective rate of the experimental group was 96.8% (35/37), which was higher than that of the control group (84.3% (31/37), P 2) decreased in both groups, while the levels of partial pressure of oxygen (PaO2), forced expiratory volume in one second (FEV1), and FEV1/forced vital capacity (FVC) increased. Conclusion: The combination of Pingchuan Guben Capsules and Budgefu has good clinical efficacy and safety in stable patients with moderate to severe chronic obstructive pulmonary disease.展开更多
文摘目的:探讨平喘固本胶囊联合布地格福对中重度慢性阻塞性肺疾病稳定期的效益。方法:选取2021年11月~2023年11月在广元市中医院呼吸与危重症医学科门诊的慢阻肺稳定期(C、D组) (肺肾两虚证)患者75例,随机分为对照组(单用布地格福)和试验组(平喘固本胶囊联合布地格福),治疗疗程9个月,观察中医证候、CAT评分、肺功能、血气分析及6分钟步行试验在治疗前后的改善情况,同时监测不良反应,评估药物安全性。结果:试验组总有效率为96.8% (35/37),高于对照组(84.3% (31/37), P 2)均较前降低,氧分压(PaO2)、第1秒用力呼气体积(FEV1)、FEV1/用力肺活量(FVC)水平升高。结论:平喘固本胶囊联合布地格福对中重度慢性阻塞性肺疾病稳定期患者具有较好的临床疗效,具有良好的安全性。Objective: To explore the efficacy of Pingchuan Guben Capsules combined with Budgefu in the stable phase of moderate to severe chronic obstructive pulmonary disease. Method: 75 patients with stable chronic obstructive pulmonary disease (COPD) (Group C and D) (lung kidney deficiency syndrome) who were treated in the Respiratory and Critical Care Medicine Clinic of Guangyuan Traditional Chinese Medicine Hospital from November 2021 to November 2023 were randomly divided into a control group (treated with Budgefu alone) and an experimental group (treated with Pingchuan Guben Capsules combined with Budgefu). The treatment course was 9 months. The improvement of TCM syndrome, CAT score, lung function, blood gas analysis, and 6-minute walk test before and after treatment were observed, and adverse reactions were monitored to evaluate drug safety. Result: The total effective rate of the experimental group was 96.8% (35/37), which was higher than that of the control group (84.3% (31/37), P 2) decreased in both groups, while the levels of partial pressure of oxygen (PaO2), forced expiratory volume in one second (FEV1), and FEV1/forced vital capacity (FVC) increased. Conclusion: The combination of Pingchuan Guben Capsules and Budgefu has good clinical efficacy and safety in stable patients with moderate to severe chronic obstructive pulmonary disease.
